Loading
This study tests TROP-2-directed treatment; the registry reports that it is terminated.
The registry lists NCT04601285 as terminated, last updated 2023-07-06. Enrolment is 25 actual participants. Interventions: JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection). Primary measures include First Cycle Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated Dose(MTD); Number of participants with adverse events (AEs). The registry reason for stopping is: Sponsor has adjusted study development plan and terminated this clinical study. No results are posted in the registry; this does not exclude separate publications.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/